Flumechin Chemische Eigenschaften,Einsatz,Produktion Methoden
R-S?tze Betriebsanweisung:
R36/37/38:Reizt die Augen, die Atmungsorgane und die Haut.
S-S?tze Betriebsanweisung:
S22:Staub nicht einatmen.
S24/25:Berührung mit den Augen und der Haut vermeiden.
S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
S27:Beschmutzte, getr?nkte Kleidung sofort ausziehen.
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
Beschreibung
Flumequine is a synthetic antibiotic belonging to the second-generation quinolone group and is mainly active against Gram negative bacteria. It is currently the only non-humans shared broad-spectrum antimicrobial veterinary drug. It is taken as the substitute product of norfloxacin. It has a strong bactericidal activity with excellent efficacy in the treatment of animal bacterial diseases. Its main effect is to inhibit bacterial deoxy nucleic acid (DNA) gyrase, interfering with the deoxyribonucleic acid (DNA) synthesis, thereby causing failure of cell for further division, and thus playing the role of killing bacteria. It is used in bovine, ovine, chicken, rabbits, goats, horses and salmonidae, however the establishment of MRLs was only requested for non-lactating cattle, pigs, sheep, chicken and salmonidae.
Chemische Eigenschaften
White Crystalline Solid
Verwenden
Flumequine is a fluoroquinolone compound with antimicrobial activity against Gram-negative organisms. It is used in the treatment of enteric infections in food animals and in the treatment of bacterial infections in farmed fish. Flumequine is replacing oxolinic acid in aquaculture because of its more appropriate pharmacokinetic profile and lower effective doses (Treves-Brown 2000). Flumequine also has limited use in humans for the treatment of urinary tract infections.
Pharmazeutische Anwendungen
A tricyclic fluorinated 4-quinolone, with activity similar to that of nalidixic acid in vitro, although it is somewhat more active against some Enterobacteriaceae.
Following escalating oral doses of 400, 800 or 1200 mg, mean peak plasma levels reached at 2 h are 13.5, 23.8 and 31.9 mg/L, respectively. The apparent elimination half-life is about 7 h. The main metabolite, hydroxyflumequine, is much more rapidly eliminated. About 60% of a dose appears in the urine, mostly in the form of conjugates. Urinary concentrations following an 800 mg dose are 10–35 mg/L, with a peak of 105 mg/L. It has no effect on the pharmacokinetics of theophylline.
Flumequine is generally well tolerated, side effects being mainly mild gastrointestinal tract disturbances, rashes, dizziness and confusion.
It is principally used in uncomplicated urinary tract infections.
Flumechin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte